News

Trump's Win, Economic Challenges Lead to Tougher Outlook for Renewable Energy Stocks: Morgan Stanley

The recent U.S. presidential election results, including a Republican sweep, have raised questions about the future of renewable energy under President-elect Donald Trump’s leadership. Morgan Stanley’s report evaluates the economic impact on renewables under various policy scenarios and its effects on earnings. The analyst has adjusted its view on the clean tech industry to “In-Line” from “Attractive.” Also Read: Solar, Renewables Stocks Crash After Trump Win: Should You Buy Now At Cheap Valuati

Starbucks (NASDAQ:SBUX) Still Has Room for Improvement Before Buying

“The customer is always right” is a credo that is often used and applies especially to consumer-facing businesses like Starbucks (SBUX). Throughout its history, the coffee franchise’s focus on the customer experience and product quality has paid off remarkably. After all, the Starbucks brand is estimated to be worth $60.7 billion, making it the 15th most valuable brand in the world. But even with all of this success, the company still has immense room for improvement. Indeed, Starbucks’ sales ha

Nvidia results in focus as stock market's election boost stalls

Nvidia Corp's results in the coming week could guide the U.S. stock market on its next path, as investors turn their focus to the technology sector and artificial intelligence trade after an election-fueled rally stalled. A nearly 800% run in shares of Nvidia over the past two years, driven by its gold standard AI business, has propelled the semiconductor company to the world's top spot by market value. That heft gives Nvidia huge sway in market benchmarks, such as the S&P 500 and Nasdaq 100, while its results on Nov. 20 will also be a gauge for the market's appetite for tech stocks, the AI trade and sentiment for equities broadly, investors said.

What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?

On Friday, Vir Biotechnology, Inc. (NASDAQ:VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 study evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa (PEG-IFNα), in participants with chronic hepatitis B. Chronic hepatitis B (CHB) is a long-lasting, inflammatory liver disease caused by the hepatitis B virus (HBV). The World Health Organization estimates that 254 million people live with CHB, and an estimated 1.1 million yearly deaths

Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline

On Friday, Eyenovia, Inc. (NASDAQ:EYEN) stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company’s Optejet dispensing platform pediatric progressive myopia. Progressive myopia is a type of nearsightedness that worsens over time due to the eyeball growing too long. The company said that an independent Data Review Committee (DRC) reviewed the CHAPERONE data and found that the trial is not meeting

Impossible Burger Moves a Step Closer to Sales in Key EU Market

(Bloomberg) -- Impossible Foods Inc. obtained a second food-safety clearance in the European Union, bringing the company closer to selling its plant-based burger in the world’s biggest market for alternative meats.Most Read from BloombergUnder Trump, Prepare for New US Transportation PrioritiesZimbabwe City of 700,000 at Risk of Running Dry by Year-EndSaudi Neom Gets $3 Billion Loan Guarantee From Italy Export Credit Agency SaceThe Urban-Rural Divide Over Highway Expansion and EmissionsThe Europ

Solid US retail sales in October underscore economy's resilience

WASHINGTON (Reuters) -U.S. retail sales increased slightly more than expected in October as households boosted purchases of motor vehicles and electronic goods, suggesting the economy kicked off the fourth quarter on a strong note. The fairly upbeat sales report on Friday, which was accompanied by sharp upward revisions to September's data, together with news of a rebound in import prices last month, prompted traders to pare back expectations that the Federal Reserve would cut interest rates in December. Fed Chair Jerome Powell said on Thursday "the economy is not sending any signals that we need to be in a hurry to lower rates."